Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
Status:
Completed
Trial end date:
2019-09-04
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the pharmacokinetic (PK) and safety of Kimyrsa
versus the approved oritavancin formulation in subjects with acute bacterial skin and skin
structure infection (ABSSSI). Kimyrsa adjusts the infusion time, concentration and
reconstitution/administration solutions of a single 1200 mg intravenous (IV) infusion of
oritavancin